A Novel Wogonin Derivative Induces Apoptosis in PC-3M Cells by Targeting Mitochondrial Dysfunction and Activating the...

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Cancer Research

Background:

• Current cancer therapies face limitations in efficacy and distribution.
• Wogonin shows antitumor potential but suffers from poor solubility and limited distribution.
• Mitochondrial-targeted drug design can enhance anticancer effects.

Purpose of the Study:

• To design and synthesize novel wogonin derivatives for improved anticancer activity.
• To investigate the mitochondrial targeting and mechanism of action of a lead derivative, Mito-WO-8.
• To explore the potential interaction of Mito-WO-8 with mitochondrial targets like GPD2.

Main Methods:

• Synthesis and in vitro evaluation of 27 wogonin derivatives.
• Mitochondrial accumulation and dysfunction assays (ROS, membrane potential, MPTP).
• Transcriptome analysis, network analysis, Western blot, and qPCR to elucidate signaling pathways.
• Binding affinity studies using molecular docking.

Main Results:

• Nine novel wogonin triphenylphosphine derivatives demonstrated in vitro antitumor activity.
• Mito-WO-8 showed potent activity against PC-3M cells, 15-fold higher than wogonin.
• Mito-WO-8 enhanced mitochondrial accumulation, induced mitochondrial dysfunction, and activated the ROS-p38/MAPK pathway.
• Mito-WO-8 exhibited stronger binding affinity to mitochondrial GPD2 than wogonin.

Conclusions:

• Mito-WO-8 effectively targets mitochondria, induces mitochondrial damage and apoptosis through the ROS-p38/MAPK pathway.
• The enhanced mitochondrial enrichment and specific binding to GPD2 suggest a novel targeted antitumor mechanism.
• Mito-WO-8 represents a promising lead compound for developing improved mitochondrial-targeted cancer therapies.